Research programme: protein kinase degrader antibody conjugates - Crossfire Oncology
Alternative Names: DAC - Crossfire Oncology; degrader antibody conjugate - Crossfire OncologyLatest Information Update: 23 Nov 2023
Price :
$50 *
At a glance
- Originator Crossfire Oncology
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 06 Oct 2023 Early research in Cancer in Netherlands (Parenteral) before October 2023 (Crossfire Oncology pipeline, October 2023)